The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.
Navid SobhaniGiandomenico RovielloSilvia P CoronaMaurizio ScaltritiAnna IanzaMarina BortulFabrizio ZanconatiDaniele GeneraliPublished in: Journal of cellular biochemistry (2018)
Breast cancer (BC) is the second most common cause of cancer-related deaths in women worldwide. The availability of reliable biomarkers of response/resistance to cancer treatments would benefit patients and clinicians allowing for a better selection of BC patients most likely to respond to a specific treatment. Phosphatidylinositol 3-kinase (PI3K) enzymes are involved in numerous cellular- functions and processes. The gene encoding for PI3K catalytic subunit p110α is mutated in 20-40% of BC. We performed a meta-analysis of the current literature on randomized clinical trials, investigating the role of PIK3CA mutational status as prognostic factor, and predictor of response to anti-cancer treatments. Overall 1929 cases were included. The pooled analysis confirmed that the presence of a PIK3CA mutation represents an independent negative prognostic factor (HR = 1.67, 95%CI: 1.15-2.43; P = 0.007) in BC, as previously reported. As PI3K signaling is also a result of other pathways' hyperactivation, further investigation of potential biomarkers able to predict likelihood of response to anti-PI3K/mTOR, anti-HER2, and other TKRs is warranted in future randomized clinical trials.
Keyphrases
- prognostic factors
- end stage renal disease
- newly diagnosed
- ejection fraction
- protein kinase
- chronic kidney disease
- peritoneal dialysis
- systematic review
- adipose tissue
- palliative care
- polycystic ovary syndrome
- patient reported outcomes
- gene expression
- combination therapy
- dna methylation
- lymph node metastasis
- double blind
- crystal structure